About Anjan Drug Private Limited
Data last updated:
Anjan Drug Private Limited is a private limited company based in Chengalpattu, Tamil Nadu, India, a subsidiary of Sekhmet Pharmaventures Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 01 August 1990 and has been in existence for over 36 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24231TN1990PTC019461. Its GSTIN is 33AAACA5168N1ZJ (Tamil Nadu).
The company has an authorised share capital of ₹26.1 Cr and a paid-up capital of ₹5.88 Cr. It was formerly known as Anjan Drugs Private Limited. It is led by directors including Anil Khubchandani and Pagadala Baskarannarayanan.
Its last annual general meeting (AGM) was held on 30 December 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot No.109 & 116 Sidcopharmaceutical I Estate Alathur – 603 110, Chengalpattu, Tamil Nadu, India – 603110.
As per the financials filed for FY 2025, the company reported a revenue of ₹293.42 Cr, a decline of 14% compared to the previous year. For the same year it recorded a net profit of ₹49.98 Cr (net margin 17%) and EBITDA of ₹82.64 Cr (EBITDA margin 28.2%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years.
The company has about 297 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Anjan Drug. As per MCA filings, the company has open charges of ₹92.9 Cr and satisfied charges of ₹295.76 Cr on record. Court records list 43 cases involving the company, including 21 filed by the company and 22 filed against it; 1 case is pending. The company has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 acquisition), with disclosed funding of ₹18.57 Cr; the latest was in October 2020. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Megafine Pharma Private Limited with revenue of ₹310.01 Cr. The company has 18 MSME Form 1 returns on record between 2019 and 2024, listing 958 overdue payments to 94 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anjandrug.net.
Company details
Contact details
Anjan Drug Private Limited's registered office is in Chengalpattu, Tamil Nadu. Its website is anjandrug.net. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No.109 & 116 Sidcopharmaceutical I Estate Alathur – 603 110, Chengalpattu, Tamil Nadu, India – 603110
- IndustryPharma, API Manufacturers
To see the full contact details of Anjan Drug Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Anjan Drug operates one associated brand: Anjan Drug. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients for CNS disorders are manufactured. | anjandrug.net |
Business activity
The main business activity of Anjan Drug is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Anjan Drug Private Limited, buy the company report.
Financials of Anjan Drug Private Limited
FY 2024 filings availableAnjan Drug Private Limited reported revenue of ₹293.42 Cr (down 14% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 14% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 16%. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹82.64 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹49.98 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 28.2% | ||||
| Net Profit Margin | 17% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Anjan Drug Private Limited, buy the company report.
Board of directors of Anjan Drug Private Limited
Anjan Drug has 8 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anil Khubchandani | Director | 12 Oct 2023 | 3 Years 0 Months | Current |
| Lakshay Kataria | Additional Director | 01 Apr 2025 | 1 Years 6 Months | Current |
| Pagadala Baskarannarayanan | Director | 11 Jan 2023 | 3 Years 9 Months | Current |
| Vivek Chhachhi Also directs: CX Advisors LLP, DCM Nouvelle Limited, DCM Nouvelle Specialty Chemicals Limited and 3 more | Nominee Director | 09 Oct 2020 | 6 Years 0 Months | Current |
| Chinnannan Kalaichelvan | Director | 01 Aug 1990 | 36 Years 2 Months | Current |
| Santosh Kumar Mahil Also directs: Sekhmet Pharmaventures Private Limited, Optimus Life Science Private Limited, Optimus Drugs Private Limited and 1 more | Director | 26 Jun 2025 | 1 Years 4 Months | Current |
Peer comparison
Anjan Drug Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Megafine Pharma Private Limited | ₹310.01 Cr (FY 2025) | -5.0% | Mumbai, Maharashtra, India | |||
| Bal Pharma Limited | ₹305.29 Cr (FY 2025) | -11.0% | Bangalore, Karnataka, India | |||
| Optrix Laboratories Private Limited | ₹304.7 Cr (FY 2020) | 43.0% | Hyderabad, Telangana, India | |||
| Ajinomoto Bio-Pharma Services India Private Limited | ₹301.41 Cr (FY 2025) | 56.0% | Anakapalle, Andhra Pradesh, India | |||
| Alembic Limited | ₹296.78 Cr (FY 2025) | 40.0% | Vadodara, Gujarat, India | |||
| Anjan Drug Private Limitedthis company | ₹293.42 Cr (FY 2025) | ₹49.98 Cr | 17% | -14.0% | 297 | Chengalpattu, Tamil Nadu, India |
| Arene Life Sciences (Unit 3) Private Limited | ₹287.8 Cr (FY 2025) | 53.0% | Hyderabad, Telangana, India | |||
| Cdymax (India) Pharma Private Limited | ₹284.85 Cr (FY 2025) | 12.0% | Bangalore, Karnataka, India | |||
| Vijayasri Organics Private Limited | ₹280.5 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Anjan Drug Private Limited, buy the company report.
Auditor
Anjan Drug Private Limited is audited by BSR & CO. LLP, for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BSR & CO. LLP, | FY 2023 | 101248W/W-100022 |
Shareholding
The shareholding of Anjan Drug Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Anjan Drug Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 Mar 2022 | 100548265 | Others | ₹15 Cr | Open | |
| 21 Oct 2021 | 100495271 | Hdfc Bank Limited | ₹31.2 Cr | Open | |
| 01 Jun 2021 | 100498491 | Others | ₹15 Cr | Open | |
| 22 Apr 2021 | 100464244 | Axis Bank Limited | ₹31.7 Cr | Open | |
| 09 Jun 2022 | 100584531 | Hdfc Bank Limited | ₹14.5 Cr | Satisfied |
To see the full charge records of Anjan Drug Private Limited, buy the company report.
Total charge records: 21 View all charges
Deals & funding
Anjan Drug Private Limited has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 acquisition), with disclosed funding of ₹18.57 Cr; the latest was in October 2020.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2019 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Dec 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Aug 2018 | Secondary share transfer | Undisclosed | Buyer: Chennai Chemicals Private Limited Seller: InvAscent |
| Aug 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jun 2009 | Funding round | ₹16 Cr | Investors: InvAscent |
To see the full deal history of Anjan Drug Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Anjan Drug Private Limited has 43 court cases on record: 21 filed by Anjan Drug, 22 filed against it. 1 case is pending and 42 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 30 | 19 | 0 |
| High courts | 12 | 3 | 1 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 43)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Execution petition | Filed against the company by Adhunik Transport Organisation Ltd | Disposed |
| Madras High Court | Appeal | Filed against the company | Pending |
| District court, Chennai, Tamil Nadu | Petition | Filed against the company by an individual | Disposed |
| District court, Tiruvallur, Tamil Nadu | Criminal case | Filed against the company by an individual | Disposed |
| District court, Tiruvallur, Tamil Nadu | Criminal complaint | Filed against the company by an individual | Disposed |
To see the full case history of Anjan Drug Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Anjan Drug Private Limited has 18 MSME Form 1 returns on record between 2019 and 2024, listing 958 overdue payments to 94 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 94)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Aditya Better Containers Pvt. Ltd., | |||
| Cephas Life Sciences Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Perfect Packings & Seals |
To see the full MSME payment records of Anjan Drug Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Anjan Drug Private Limited has a workforce of 297 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
GST
Anjan Drug has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACA5168N1ZJ | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Anjan Drug Private Limited, buy the company report.
Recent activity
Anjan Drug Private Limited has 21 board changes on record since 1990: 8 appointments and 13 cessations. The latest: Santosh Kumar Mahil ceased to be Additional Director on 21 Dec 2025.
64 earlier events are in the company report.
Frequently asked questions
Anjan Drug is an active private limited company based in Chengalpattu, Tamil Nadu, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 01 August 1990 (36+ years old) and is registered under CIN U24231TN1990PTC019461.
Anjan Drug has 8 current directors:
- Anil Khubchandani - Director
- Lakshay Kataria - Additional Director
- Pagadala Baskarannarayanan - Director
- Vivek Chhachhi - Nominee Director
- Chinnannan Kalaichelvan - Director
- Santosh Kumar Mahil - Director
- Sumit Mohan Nadgir - Director
- Devi Thumati Krishnaraj - Officer In Default
The latest financial statements of Anjan Drug on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 December 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Anjan Drug is 33AAACA5168N1ZJ, registered in Tamil Nadu.
The CIN (Corporate Identification Number) of Anjan Drug is U24231TN1990PTC019461. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Anjan Drug has 43 court cases on record: 21 filed by the company and 22 filed against it. 1 is pending. Most are in the district courts.
Anjan Drug was incorporated on 01 August 1990, making it 36+ years old. It is registered with the Registrar of Companies, Chennai.
Anjan Drug has 10 deals on record (6 secondary share transfers, 3 funding rounds, 1 acquisition), with disclosed funding of ₹18.57 Cr; the latest was in October 2020.
The peers of Anjan Drug by revenue are Megafine Pharma Private Limited, Bal Pharma Limited, Optrix Laboratories Private Limited, Ajinomoto Bio-Pharma Services India Private Limited, Alembic Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Santosh Kumar Mahil ceased to be Additional Director on 21 Dec 2025. Sumit Mohan Nadgir ceased to be Additional Director on 21 Dec 2025. Devi Thumati Krishnaraj was appointed as Officer In Default on 16 Jul 2025. Anjan Drug has 21 board changes on record in total.
Anjan Drug has 18 MSME Form 1 returns on record between 2019 and 2024, listing 958 overdue payments to 94 micro and small suppliers. The latest return was filed on 18 Apr 2024.
Anjan Drug can be reached through the website anjandrug.net. Its registered office is in Chengalpattu, Tamil Nadu, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
